Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marc A Pfeffer

Showing results (441-450 of 520) with videos related to

Pageof 52
Sort By:
Journal of Cardiac Failure|April 8, 2026
Performance of the HFpEF-ABA, H<sub>2</sub>FPEF, and HFA-PEFF Algorithms in HFpEF: A Participant-Level Pooled Analysis of Randomized Clinical TrialsJohn W Ostrominski, Fernando A Lara Lince, Brian L Claggett, et al.
European Journal of Heart Failure|June 9, 2025
Application of a transthyretin amyloid cardiomyopathy score to heart failure with mildly reduced or preserved ejection fractionRiccardo M Inciardi, Muthiah Vaduganathan, Brian Claggett, et al.
Circulation. Heart Failure|March 12, 2021
Cardiac and Noncardiac Disease Burden and Treatment Effect of Sacubitril/Valsartan: Insights From a Combined PARAGON-HF and PARADIGM-HF AnalysisLuis E Rohde, Brian L Claggett, Emil Wolsk, et al.
Journal of the American College of Cardiology|August 3, 2019
Age-Related Characteristics and Outcomes of Patients With Heart Failure With Preserved Ejection FractionJasper Tromp, Li Shen, Pardeep S Jhund, et al.
Circulation|October 20, 2004
Mortality and morbidity reduction with Candesartan in patients with chronic heart failure and left ventricular systolic dysfunction: results of the CHARM low-left ventricular ejection fraction trialsJames B Young, Mark E Dunlap, Marc A Pfeffer, et al.
Journal of the American College of Cardiology|August 27, 2025
Adiposity-Related Anthropometrics and Clinical Outcomes in Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Participant-Level Pooled Analysis of Randomized Clinical TrialsJohn W Ostrominski, Mats C Højbjerg Lassen, Jawad H Butt, et al.
Journal of the American College of Cardiology|September 2, 2025
Natriuretic Peptides, Body Mass Index, and Clinical Outcomes in Heart Failure with Mildly Reduced or Preserved Ejection FractionJohn W Ostrominski, Brendon L Neuen, Brian L Claggett, et al.
JAMA Cardiology|August 7, 2024
Rates of Sudden Death After Myocardial Infarction-Insights From the VALIANT and PARADISE-MI TrialsJames P Curtain, Marc A Pfeffer, Eugene Braunwald, et al.
European Journal of Heart Failure|September 30, 2017
Prognostic importance of emerging cardiac, inflammatory, and renal biomarkers in chronic heart failure patients with reduced ejection fraction and anaemia: RED-HF studyPaul Welsh, Lei Kou, Changhong Yu, et al.
JAMA|September 1, 2004
Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trialJames A de Lemos, Michael A Blazing, Stephen D Wiviott, et al.
Pageof 52

Showing results (441-450 of 520) with videos related to

Sort By:
Pageof 52
Journal of Cardiac Failure|April 8, 2026
Performance of the HFpEF-ABA, H<sub>2</sub>FPEF, and HFA-PEFF Algorithms in HFpEF: A Participant-Level Pooled Analysis of Randomized Clinical TrialsJohn W Ostrominski, Fernando A Lara Lince, Brian L Claggett, et al.
European Journal of Heart Failure|June 9, 2025
Application of a transthyretin amyloid cardiomyopathy score to heart failure with mildly reduced or preserved ejection fractionRiccardo M Inciardi, Muthiah Vaduganathan, Brian Claggett, et al.
Circulation. Heart Failure|March 12, 2021
Cardiac and Noncardiac Disease Burden and Treatment Effect of Sacubitril/Valsartan: Insights From a Combined PARAGON-HF and PARADIGM-HF AnalysisLuis E Rohde, Brian L Claggett, Emil Wolsk, et al.
Journal of the American College of Cardiology|August 3, 2019
Age-Related Characteristics and Outcomes of Patients With Heart Failure With Preserved Ejection FractionJasper Tromp, Li Shen, Pardeep S Jhund, et al.
Circulation|October 20, 2004
Mortality and morbidity reduction with Candesartan in patients with chronic heart failure and left ventricular systolic dysfunction: results of the CHARM low-left ventricular ejection fraction trialsJames B Young, Mark E Dunlap, Marc A Pfeffer, et al.
Journal of the American College of Cardiology|August 27, 2025
Adiposity-Related Anthropometrics and Clinical Outcomes in Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Participant-Level Pooled Analysis of Randomized Clinical TrialsJohn W Ostrominski, Mats C Højbjerg Lassen, Jawad H Butt, et al.
Journal of the American College of Cardiology|September 2, 2025
Natriuretic Peptides, Body Mass Index, and Clinical Outcomes in Heart Failure with Mildly Reduced or Preserved Ejection FractionJohn W Ostrominski, Brendon L Neuen, Brian L Claggett, et al.
JAMA Cardiology|August 7, 2024
Rates of Sudden Death After Myocardial Infarction-Insights From the VALIANT and PARADISE-MI TrialsJames P Curtain, Marc A Pfeffer, Eugene Braunwald, et al.
European Journal of Heart Failure|September 30, 2017
Prognostic importance of emerging cardiac, inflammatory, and renal biomarkers in chronic heart failure patients with reduced ejection fraction and anaemia: RED-HF studyPaul Welsh, Lei Kou, Changhong Yu, et al.
JAMA|September 1, 2004
Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trialJames A de Lemos, Michael A Blazing, Stephen D Wiviott, et al.
Pageof 52